Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)

被引：0
|
作者：
Genovese, Mark C. [1 ]
Glover, Josephine [2 ]
Matsunaga, Nobuhito [3 ]
Chisholm, Diane [4 ]
Alten, Rieke [5 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Coephycient Pharmaceut Consultancy, Guildford, Surrey, England
[3] Fujifilm Kyowa Kirin Biol, Chiyoda Ku, Tokyo, Japan
[4] Fujifilm Kyowa Kirin Biol, Galashiels, Scotland
[5] Univ Med Berlin, Berlin, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2799
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
    Cohen, Stanley
    Genovese, Mark C.
    Choy, Ernest
    Perez-Ruiz, Fernando
    Matsumoto, Alan
    Pavelka, Karel
    Pablos, Jose L.
    Rizzo, Warren
    Hrycaj, Pawel
    Zhang, Nan
    Shergy, William
    Kaur, Primal
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (10) : 1679 - 1687
  • [32] Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: A 52-week phase III randomised study
    Matsuno, H.
    Kang, Y. M.
    Okada, M.
    Lee, S-, I
    Park, S-H
    Sheen, D. H.
    Sato, M.
    Hagino, A.
    Lee, J.
    Shin, S.
    Song, Y. W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (05) : 1025 - 1033
  • [33] Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-Blind, Monotherapy Study in Patients with Active Rheumatoid Arthritis with Intolerance or Inadequate Response to Methotrexate
    Burmester, Gerd
    Lin, Yong
    Patel, Rahul
    van Adelsberg, Janet
    Mangan, Erin
    van Hoogstraten, Hubert
    Bauer, Deborah
    Ignacio Vargas, Juan
    Lee, Eun Bong
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [34] EFFICACY AND SAFETY OF SARILUMAB VERSUS ADALIMUMAB IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MONOTHERAPY STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INTOLERANCE OR INADEQUATE RESPONSE TO METHOTREXATE
    Burmester, G.
    Lin, Y.
    Mangan, E.
    Van Hoogstraten, H.
    Vargas, J.
    Lee, E.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 26 - 26
  • [35] Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-Severe Rheumatoid Arthritis: Results of a Randomized Double-Blind Study
    Zubrzycka-Sienkiewicz, Anna
    Misterska-Skora, Maria
    Socik-Pojawa, Malgorzata
    Klama, Kamilla
    Ullman, Martin
    Petit-Frere, Corinne
    Illes, Andras
    Baker, Peter
    Monnet, Joelle
    Morais, Jeremy
    Brzezicki, Jan
    RHEUMATOLOGY, 2024, 63
  • [36] COMPARISON OF THE EFFICACY, SAFETY AND IMMUNOGENICITY OF A PROPOSED BIOSIMILAR MSB11456 WITH TOCILIZUMAB REFERENCE PRODUCT IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A RANDOMIZED DOUBLE-BLIND STUDY
    Zubrzycka-Sienkiewicz, Anna
    Misterska-Skora, Maria
    Socik-Pojawa, Malgorzata
    Klama, Kamilla
    Ullman, Martin
    Petit-Frere, Corinne
    Illes, Andras
    Baker, Peter
    Monnet, Joelle
    Morais, Jeremy
    Brzezicki, Jan
    RHEUMATOLOGY, 2024, 63
  • [37] Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study
    Maharaj, Narendra
    Uppada, Dharma Rao
    Mareddy, Naveen Reddy
    Pundra, Pramod Reddy
    Batalov, Anastas
    Ivanova, Delina
    Staykova, Nedyalka
    Baranauskaite, Asta
    Hassan, Laila
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1069 - 1070
  • [38] Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
    Maharaj, Narendra
    Uppada, Dharma Rao
    Reddy, Naveen
    Reddy, Pramod
    Batalov, Anastas
    Lvanova, Delina
    Staykova, Nedyalka
    Baranauskaite, Asta
    Hassan, Laila Amirali
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [39] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd, Burmester
    Edit, Drescher
    Pawel, Hrycaj
    David, Chien
    Pan Zhiying
    Stanley, Cohen
    CLINICAL RHEUMATOLOGY, 2020, 39 (11) : 3341 - 3352
  • [40] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd Burmester
    Edit Drescher
    Pawel Hrycaj
    David Chien
    Zhiying Pan
    Stanley Cohen
    Clinical Rheumatology, 2020, 39 : 3341 - 3352
12345